Entegard Dosage/Direction for Use

The usual dose of entecavir in nucleoside treatment-naive patients is 500 micrograms once daily, with or without food. A dose of 1 mg once daily should be used in patients with a history of hepatitis B viraemia during lamivudine therapy or with known resistance to lamivudine. For details of reduced doses to be used in patients with renal impairment, see as follows: Administration in Renal Impairment: Doses of entecavir should be reduced in patients with renal impairment according to creatinine clearance (CC) as follows: CC 30 to 49 mL/minute: 250 micrograms once daily in nucleoside treatment-naïve patients; 500 micrograms once daily in lamivudine-refractory patients or as prescribed by the physician.
CC 10 to 29 mL/minute: 150 micrograms once daily in nucleoside treatment-naïve patients; 300 micrograms once daily in lamivudine-refractory patients or as prescribed by the physician.
CC less than 10 mL/minute: 50 micrograms once daily in nucleoside treatment-naïve patients; 100 micrograms once daily in lamivudine-refractory patients or as prescribed by the physician.
Patients receiving hemodialysis should receive the appropriate dose after each dialysis session.